Andrei R. Shustov
YOU?
Author Swipe
View article: Brentuximab vedotin plus chemotherapy for the treatment of front-line systemic anaplastic large cell lymphoma: subgroup analysis of the ECHELON-2 study at 5 years’ follow-up
Brentuximab vedotin plus chemotherapy for the treatment of front-line systemic anaplastic large cell lymphoma: subgroup analysis of the ECHELON-2 study at 5 years’ follow-up Open
Trial registration: ClinicalTrials.gov number: NCT01777152
View article: Maintenance therapy with romidepsin after autologous stem-cell transplant for peripheral T-cell lymphoma
Maintenance therapy with romidepsin after autologous stem-cell transplant for peripheral T-cell lymphoma Open
Patients with peripheral T-cell lymphoma (PTCL) have suboptimal outcomes. Autologous hematopoietic stem-cell transplantation (AHCT) is a therapeutic strategy for patients in first complete remission (CR1) or first partial remission (PR1), …
View article: Geographic EBV variants confound disease-specific variant interpretation and predict variable immune therapy responses
Geographic EBV variants confound disease-specific variant interpretation and predict variable immune therapy responses Open
Epstein-Barr virus (EBV) is a potent carcinogen linked to hematologic and solid malignancies and causes significant global morbidity and mortality. Therapy using allogeneic EBV-specific lymphocytes shows promise in certain populations, but…
View article: Phase II study of dose-adjusted EPOCH as initial therapy for adults with high-risk acute lymphoblastic leukemia
Phase II study of dose-adjusted EPOCH as initial therapy for adults with high-risk acute lymphoblastic leukemia Open
Treatments for adults with newly-diagnosed acute lymphoblastic leukemia (ALL) may be prohibitively toxic and/or resource-intense. To address this, we performed a phase II study of dose-adjusted etoposide, prednisone, vincristine, cyclophos…
View article: T057: Circulating tumor DNA in classical Hodgkin lymphoma patients treated with pembrolizumab and chemotherapy: dynamic response assessment and correlation with baseline total metabolic tumor volume
T057: Circulating tumor DNA in classical Hodgkin lymphoma patients treated with pembrolizumab and chemotherapy: dynamic response assessment and correlation with baseline total metabolic tumor volume Open
Figure 1: A: Progression-free survival; B: Scatter-plot demonstrating correlation of baseline TMTV with ctDNA levels; C: Spider-plot of ctDNA levels at various time points during the study color-coded by interim-PET results Introduction: W…
View article: Role of stem cell transplant in CD30+ PTCL following frontline brentuximab vedotin plus CHP or CHOP in ECHELON-2
Role of stem cell transplant in CD30+ PTCL following frontline brentuximab vedotin plus CHP or CHOP in ECHELON-2 Open
Peripheral T-cell lymphomas (PTCLs) are a heterogeneous group of aggressive non-Hodgkin lymphomas, the majority of which have high relapse rates following standard therapy. Despite use of consolidative stem cell transplant (SCT) following …
View article: The ECHELON-2 Trial: 5-year results of a randomized, phase III study of brentuximab vedotin with chemotherapy for CD30-positive peripheral T-cell lymphoma
The ECHELON-2 Trial: 5-year results of a randomized, phase III study of brentuximab vedotin with chemotherapy for CD30-positive peripheral T-cell lymphoma Open
View article: TCL-150: The ECHELON-2 Trial: 5-Year Results of a Randomized, Double-Blind, Phase 3 Study of Brentuximab Vedotin and CHP (A+CHP) Versus CHOP in Frontline Treatment of Patients with CD30-Positive Peripheral T-Cell Lymphoma
TCL-150: The ECHELON-2 Trial: 5-Year Results of a Randomized, Double-Blind, Phase 3 Study of Brentuximab Vedotin and CHP (A+CHP) Versus CHOP in Frontline Treatment of Patients with CD30-Positive Peripheral T-Cell Lymphoma Open
Objective Brentuximab vedotin (BV) plus cyclophosphamide, doxorubicin, and prednisone (A+CHP) significantly prolonged progression-free survival (PFS) and overall survival (OS) versus cyclophosphamide, doxorubicin, vincristine, and predniso…
View article: Dose-dense brentuximab vedotin plus ifosfamide, carboplatin, and etoposide for second-line treatment of relapsed or refractory classical Hodgkin lymphoma: a single centre, phase 1/2 study
Dose-dense brentuximab vedotin plus ifosfamide, carboplatin, and etoposide for second-line treatment of relapsed or refractory classical Hodgkin lymphoma: a single centre, phase 1/2 study Open
View article: Fatal Microangiopathic Hemolytic Anemia Due to Sézary Syndrome
Fatal Microangiopathic Hemolytic Anemia Due to Sézary Syndrome Open
Sézary syndrome (SS) is a form of cutaneous T-cell lymphoma (CTCL), demonstrating leukemic involvement of malignant T-cells. Known systemic sequelae of SS include hemophagocytic syndrome-induced anemia, normocytic anemia secondary to bone …
View article: Outcomes and prognostic factors in angioimmunoblastic T-cell lymphoma: final report from the international T-cell Project
Outcomes and prognostic factors in angioimmunoblastic T-cell lymphoma: final report from the international T-cell Project Open
Angioimmunoblastic T-cell lymphoma (AITL) is a unique subtype of peripheral T-cell lymphoma (PTCL) with distinct clinicopathologic features and poor prognosis. We performed a subset analysis of 282 patients with AITL enrolled between 2006 …
View article: ALK-negative anaplastic large cell lymphoma: features and outcomes of 235 patients from the International T-Cell Project
ALK-negative anaplastic large cell lymphoma: features and outcomes of 235 patients from the International T-Cell Project Open
Anaplastic lymphoma kinase–negative anaplastic large cell lymphoma (ALK– ALCL) is an aggressive neoplasm of T-cell/null-cell lineage. The T-Cell Project is a global prospective cohort study that consecutively enrolled patients newly diagno…
View article: Exploratory Analysis of Brentuximab Vedotin Plus CHP (A+CHP) as Frontline Treatment for Patients with CD30-Expressing PERIPHERAL T-Cell Lymphomas (Echelon-2): Impact of Consolidative Stem Cell Transplant
Exploratory Analysis of Brentuximab Vedotin Plus CHP (A+CHP) as Frontline Treatment for Patients with CD30-Expressing PERIPHERAL T-Cell Lymphomas (Echelon-2): Impact of Consolidative Stem Cell Transplant Open
View article: Combined oral 5-azacytidine and romidepsin are highly effective in patients with PTCL: a multicenter phase 2 study
Combined oral 5-azacytidine and romidepsin are highly effective in patients with PTCL: a multicenter phase 2 study Open
Peripheral T-cell lymphomas (PTCLs) are uniquely vulnerable to epigenetic modifiers. We demonstrated in vitro synergism between histone deacetylase inhibitors and DNA methyltransferase inhibitors in preclinical models of T-cell lymphoma. I…
View article: NCCN Guidelines Insights: T-Cell Lymphomas, Version 1.2021
NCCN Guidelines Insights: T-Cell Lymphomas, Version 1.2021 Open
Hepatosplenic T-cell lymphoma (HSTCL) is a rare subtype of T-cell lymphoma associated with an aggressive clinical course and a worse prognosis. HSTCL develops in the setting of chronic immune suppression or immune dysregulation in up to 20…
View article: Outcomes of Patients with Transformed Mycosis Fungoides: Analysis from a Prospective Multicenter US Cohort Study
Outcomes of Patients with Transformed Mycosis Fungoides: Analysis from a Prospective Multicenter US Cohort Study Open
View article: Considerations for Managing Patients With Hematologic Malignancy During the COVID-19 Pandemic: The Seattle Strategy
Considerations for Managing Patients With Hematologic Malignancy During the COVID-19 Pandemic: The Seattle Strategy Open
In January 2020, the first documented patient in the United States infected with severe acute respiratory syndrome coronavirus 2 was diagnosed in Washington State. Since that time, community spread of coronavirus disease 2019 (COVID-19) in…
View article: NCCN Guidelines Insights: Primary Cutaneous Lymphomas, Version 2.2020
NCCN Guidelines Insights: Primary Cutaneous Lymphomas, Version 2.2020 Open
Mycosis fungoides (MF) is the most common subtype of cutaneous T-cell lymphoma (CTCL), and Sézary syndrome (SS) is a rare erythrodermic and leukemic subtype of CTCL characterized by significant blood involvement. Although early-stage disea…
View article: Characterizing the belinostat response in patients with relapsed or refractory angioimmunoblastic T-cell lymphoma
Characterizing the belinostat response in patients with relapsed or refractory angioimmunoblastic T-cell lymphoma Open
The BELIEF trial was an international study of belinostat in patients with relapsed or refractory (R/R) peripheral T-cell lymphoma (PTCL) that led to FDA-approval for the disease. Herein, we present a subset analysis of patients with angio…
View article: Survival outcomes of patients with extranodal natural-killer T-cell lymphoma: a prospective cohort study from the international T-cell Project
Survival outcomes of patients with extranodal natural-killer T-cell lymphoma: a prospective cohort study from the international T-cell Project Open
The Fondazione Cassa di Risparmio di Modena, the Associazione Angela Serra per la Ricerca sul Cancro, the Fondazione Italiana Linfomi, Allos Therapeutics, Spectrum Pharmaceuticals, Associazione Italiana per la Ricerca sul Cancro, and the N…
View article: An Exploratory Analysis of Brentuximab Vedotin Plus CHP (A+CHP) in the Frontline Treatment of Patients with CD30+ Peripheral T-Cell Lymphomas (ECHELON-2): Impact of Consolidative Stem Cell Transplant
An Exploratory Analysis of Brentuximab Vedotin Plus CHP (A+CHP) in the Frontline Treatment of Patients with CD30+ Peripheral T-Cell Lymphomas (ECHELON-2): Impact of Consolidative Stem Cell Transplant Open
Introduction The ECHELON-2 study (NCT01777152) demonstrated significantly longer progression-free survival (PFS) and overall survival with brentuximab vedotin plus cyclophosphamide, doxorubicin, and prednisone (A+CHP) versus CHOP in the fr…
View article: Pembrolizumab in Relapsed and Refractory Mycosis Fungoides and Sézary Syndrome: A Multicenter Phase II Study
Pembrolizumab in Relapsed and Refractory Mycosis Fungoides and Sézary Syndrome: A Multicenter Phase II Study Open
PURPOSE To assess the efficacy of pembrolizumab in patients with advanced relapsed or refractory mycosis fungoides (MF) or Sézary syndrome (SS). PATIENTS AND METHODS CITN-10 is a single-arm, multicenter phase II trial of 24 patients with a…
View article: Oral 5-azacytidine and romidepsin exhibit marked activity in patients with PTCL: a multicenter phase 1 study
Oral 5-azacytidine and romidepsin exhibit marked activity in patients with PTCL: a multicenter phase 1 study Open
The authors report a phase 1 study of romidepsin combined with oral 5-azacytidine in patients with relapsed/refractory lymphomas, including complete remissions in 3 patients with angioimmunoblastic T-cell lymphoma.
View article: Outcomes for Relapsed and Refractory Peripheral T-Cell Lymphoma Patients after Front-Line Therapy from the COMPLETE Registry
Outcomes for Relapsed and Refractory Peripheral T-Cell Lymphoma Patients after Front-Line Therapy from the COMPLETE Registry Open
Background: Outcomes for patients with peripheral T-cell lymphoma (PTCL) who fail to achieve complete response (CR) or relapse after front-line therapy are poor with lack of prospective outcomes data. Objectives: COMPLETE is a prospective …
View article: Consensus criteria for diagnosis, staging, and treatment response assessment of T-cell prolymphocytic leukemia
Consensus criteria for diagnosis, staging, and treatment response assessment of T-cell prolymphocytic leukemia Open
In a Special Report, the T-PLL International Study group presents consensus criteria for the diagnosis, staging, and treatment response assessment of patients with T-cell prolymphocytic leukemia.
View article: How I treat primary cutaneous CD30+ lymphoproliferative disorders
How I treat primary cutaneous CD30+ lymphoproliferative disorders Open
The primary cutaneous CD30+ lymphoproliferative disorders are a family of extranodal lymphoid neoplasms that arise from mature postthymic T cells and localize to the skin. Current classification systems recognize lymphomatoid papulosis (Ly…
View article: PS1070 THE ECHELON‐2 TRIAL: RESULTS OF A RANDOMIZED, DOUBLE‐BLIND PHASE 3 STUDY OF BRENTUXIMAB VEDOTIN AND CHP (A+CHP) VERSUS CHOP IN FRONTLINE TREATMENT OF PATIENTS WITH CD30+ PERIPHERAL T‐CELL LYMPHOMAS
PS1070 THE ECHELON‐2 TRIAL: RESULTS OF A RANDOMIZED, DOUBLE‐BLIND PHASE 3 STUDY OF BRENTUXIMAB VEDOTIN AND CHP (A+CHP) VERSUS CHOP IN FRONTLINE TREATMENT OF PATIENTS WITH CD30+ PERIPHERAL T‐CELL LYMPHOMAS Open
Please indicate where the abstract has been published before: The data in this abstract have been published in the Lancet (Horwitz 2019). Background: Peripheral T‐cell lymphoma (PTCL) is a heterogeneous group of aggressive non‐Hodgkin lymp…
View article: Outcomes of patients with large B‐cell lymphomas and progressive disease following CD19‐specific CAR T‐cell therapy
Outcomes of patients with large B‐cell lymphomas and progressive disease following CD19‐specific CAR T‐cell therapy Open
Diffuse large B-cell lymphoma (DLBCL) and other aggressive B-cell non-Hodgkin lymphomas (NHL) are curable with front-line chemoimmunotherapy; however, patients with relapsed or refractory (R/R) disease face poor outcomes.1 Patients who wer…
View article: Single agents vs combination chemotherapy in relapsed and refractory peripheral T‐cell lymphoma: Results from the comprehensive oncology measures for peripheral T‐cell lymphoma treatment (COMPLETE) registry
Single agents vs combination chemotherapy in relapsed and refractory peripheral T‐cell lymphoma: Results from the comprehensive oncology measures for peripheral T‐cell lymphoma treatment (COMPLETE) registry Open
Single agents have demonstrated activity in relapsed and refractory (R/R) peripheral T‐cell lymphoma (PTCL). Their benefit relative to combination chemotherapy remains undefined. Patients with histologically confirmed PTCL were enrolled in…
View article: Randomized Phase III Study of Alisertib or Investigator’s Choice (Selected Single Agent) in Patients With Relapsed or Refractory Peripheral T-Cell Lymphoma
Randomized Phase III Study of Alisertib or Investigator’s Choice (Selected Single Agent) in Patients With Relapsed or Refractory Peripheral T-Cell Lymphoma Open
PURPOSE The aim of this open-label, first-in-setting, randomized phase III trial was to evaluate the efficacy of alisertib, an investigational Aurora A kinase inhibitor, in patients with relapsed/refractory peripheral T-cell lymphoma (PTCL…